VIKEN, Sweden, May 29, 2018 (Newswire.com) - TikoMed, a specialty pharmaceutical company that focuses on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, today announces that an abstract supporting the ongoing development of its proprietary technology ILB was presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) held April 29–May 3 in Honolulu, Hawaii, USA.
The poster showed that ILB treatment in a rat model resulted in an elimination of the scar, leading to a normalized eye pressure, preventing future cell death and protection against future vascular complications.
We were excited to present these data at ARVO, one of the pre-eminent events in the ophthalmic space. We believe the ILB technology has significant potential in glaucoma and related ophthalmic conditions involving scarring in the eye and CNS. The results of these preclinical studies reinforce this belief and support the further evaluation of this technology. Our development program is on track, and we look forward to initiating a glaucoma clinical trial of our lead ILB asset later this year.
Anders Svensson, M.D., Chief Medical Officer of TikoMed
Given that current glaucoma treatments do not address the underlying pathology, a treatment that reverses the glaucomatous pathology that leads to progressive vision loss and significantly improves inner eye pressure control would be highly valuable for glaucoma patients.
The study will be performed at and in collaboration with University of Birmingham, U.K. Mr. Imran Masood, an expert in the treatment of glaucoma and retinal diseases, will be principal investigator and Prof. Peter Shah, M.D., a world-renowned key opinion leader, will be co-investigator.
TikoMed has performed a favorable meeting with MHRA and a clinical Phase 2a study is under preparation to be handed in. The study is expected to start later this year.
Source: TIKOMED AB
Share: